Price
No data yet.
Social Signal Score
Analyst Ratings
12 analystsRevenue
$0.00-100.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Chen Schor
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 102
- Beta
- 1.59
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -6.27
Financials
Revenue
$0.00-100.0%Net Income
$-21.36M-587.1%EBITDA
$-18.65M-237.0%Free Cash Flow
$-20.02M-298.1%EPS (diluted)
$-1.99-173.2%Shares Outstanding (diluted)
10.75M+558.5%Operating Expenses
$22.30MCash & Debt
$118.19MReturn of Capital
$0.00Revenue by Segment (annual)
$638.32MDividend per Share
$0.01Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-116.80M | $-16.95 |
| 2024 | $0.00 | $-117.12M | $-21.28 |
| 2023 | $0.00 | $-142.66M | $-52.96 |
| 2022 | $24.99M | $-69.79M | $-27.20 |
| 2021 | $9.73M | $-62.00M | $-32.00 |
| 2020 | $17.90M | $-36.68M | $-80.16 |
| 2019 | $995.0K | $-28.14M | $-24.32 |
| 2018 | $8.18M | $-9.30M | $-4.96 |
| 2017 | $558.52M | $-33.78M | $-20.16 |
| 2016 | $546.95M | $-1.0K | $-0.00 |
| 2015 | $510.18M | $29.00M | $18.88 |
| 2014 | $499.69M | $22.33M | $15.04 |
| 2013 | $499.69M | $22.33M | $15.04 |
| 2012 | $444.39M | $16.98M | $11.68 |
Valuation
ACEThas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
80-36.84%Social Signal Score
Mentions (7)
- Newsmarketbeat.com·3d ago·Negative
Adicet Bio's Prula-Cel Delivers 54% Lupus Remission Rate at 12 Months Adicet Bio NASDAQ: ACET reported positive clinical data for prula-cel, its investigational allogeneic gamma delta CAR-T cell therapy, in patients with systemic lupus erythematosus, or SLE, including patients with lupus nephritis.
View source ↗ - Newsseekingalpha.com·7d ago·Positive
Adicet Bio, Inc. (ACET) Discusses Positive Prula-cel Data and Plans for Pivotal Study in Lupus Nephritis Transcript Adicet Bio, Inc. (ACET) Discusses Positive Prula-cel Data and Plans for Pivotal Study in Lupus Nephritis Transcript
View source ↗ - Newszacks.com·32d ago·Neutral
Wall Street Analysts See a 258.21% Upside in Adicet Bio (ACET): Can the Stock Really Move This High? The average of price targets set by Wall Street analysts indicates a potential upside of 258.2% in Adicet Bio (ACET). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
View source ↗ - Newszacks.com·42d ago·Neutral
Here's Why You Should Add ACET Stock to Your Portfolio Now Adicet Bio advances prula-cel in autoimmune diseases while pursuing new opportunities in prostate cancer and in vivo CAR-T.
View source ↗ - Newszacks.com·52d ago·Neutral
Wall Street Analysts Think Adicet Bio (ACET) Could Surge 301.57%: Read This Before Placing a Bet The consensus price target hints at a 301.6% upside potential for Adicet Bio (ACET). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
View source ↗ - Newsmarketbeat.com·55d ago·Neutral
Adicet Bio Eyes Key Lupus Data This Quarter for Off-the-Shelf Cell Therapy Adicet Bio NASDAQ: ACET expects to report clinical data this quarter for its lead autoimmune program, ADI-001, also known as prula-cel, including results in lupus nephritis (LN) and systemic lupus erythematosus (SLE), Chief Executive Officer Chen Schor said at the 46th Annual Canaccord Genuity Growth Conference.
View source ↗ - Newszacks.com·56d ago·Positive
All You Need to Know About Adicet Bio (ACET) Rating Upgrade to Buy Adicet Bio (ACET) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
View source ↗
Earnings
Wed, Nov 4(in 4 weeks)
Consensus estimate $-1.56 per share
Typical surprise -11.5% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$-1.99 vs $-1.69miss
- Wed, May 13$-1.88 vs $-2.93beat
- Thu, Mar 12$-2.94 vs $-2.99beat
- Wed, Nov 5$-4.64 vs $-4.16miss
- Thu, Aug 7$-5.44 vs $-4.86miss
- Tue, May 6$-4.96 vs $-5.31beat
Estimates and results for ACET via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ACET officers and directors.
- Bought
- $6.6m
- Sold
- $675k
5 trades
4 trades
- Orbimed Advisors Llcsold
- Orbimed Advisors Llcsold
- Orbimed Advisors Llcsold
- Orbimed Advisors Llcsold
- Ra Capital Management, L.p.bought
- Ra Capital Management, L.p.bought
- Ra Capital Management, L.p.bought
- Orbimed Advisors Llcbought
91 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ACET.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.